Dermata Therapeutics
DRMA
6 hedge funds and large institutions have $91K invested in Dermata Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
60% less capital invested
Capital invested by funds: $226K → $91K (-$135K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$17.1K |
| 2 |
BlackRock
New York
|
+$13.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$68K |
| 2 |
Two Sigma Investments
New York
|
-$33K |
| 3 |
SCA
Sage Capital Advisors
Sioux Falls,
South Dakota
|
-$20K |
| 4 |
JP Morgan Chase
New York
|
-$17.1K |
| 5 |
TCWM
Total Clarity Wealth Management
St. Charles,
Illinois
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $33K | – | – | – |
|
|
2
BlackRock
New York
| $22K | +$13.7K | +4 | +133% |
|
|
3
Wells Fargo
San Francisco,
California
| $14K | +$17.1K | +5 | New |
|
4
Tudor Investment Corp
Stamford,
Connecticut
| $13K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $5K | +$6.83K | +2 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
|
7
JP Morgan Chase
New York
| $1K | -$17.1K | -5 | Closed |
|
|
8
Renaissance Technologies
New York
| – | -$68K | -16 | Closed |
|
|
9
Two Sigma Investments
New York
| – | -$33K | -8 | Closed |
|
|
SCA
10
Sage Capital Advisors
Sioux Falls,
South Dakota
| – | -$20K | -5 | Closed |
|
|
TCWM
11
Total Clarity Wealth Management
St. Charles,
Illinois
| – | -$1K | – | – |
|
DRMA Hedge Fund Activity: Q1 2022 in Review
6 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q1 2022, worth a combined $91K — down 60% from $226K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DRMA and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Wells Fargo, opening a new position worth an estimated $17.1K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $68K sold.
- 6 institutional investors held Dermata Therapeutics (DRMA) as of Q1 2022, down from 8 in Q4 2021.
- Funds reported $91K of Dermata Therapeutics stock for Q1 2022, down 60% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics positions in Q1 2022 and 4 closed out, a net change of -2 holders.
- The largest Dermata Therapeutics buyer in Q1 2022 was Wells Fargo, an estimated $17.1K added.
- The largest Dermata Therapeutics seller in Q1 2022 was Renaissance Technologies, an estimated $68K sold.
Based on aggregated 13F filings for Q1 2022.